Brivanib alaninate
- Generic Name
- Brivanib alaninate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24FN5O4
- CAS Number
- 649735-63-7
- Unique Ingredient Identifier
- U2Y5OFN795
- Background
Brivanib alaninate has been investigated for the treatment of Colorectal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
- First Posted Date
- 2010-12-28
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT01267253
- Locations
- 🇺🇸
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
🇺🇸Beebe Medical Center, Lewes, Delaware, United States
🇺🇸Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
Brivanib Metastatic Renal Cell Carcinoma
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT01253668
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Mucinous AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Transitional Cell CarcinomaRecurrent Uterine Corpus CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Undifferentiated CarcinomaEndometrial Adenocarcinoma
- Interventions
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT00888173
- Locations
- 🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇺🇸Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 750
- Registration Number
- NCT00640471
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada
🇨🇦Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.